Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
The alpha-glucosidase inhibitor acarbose has been used for more than 20 years in the management of hyperglycemia. Owing to its unique mode of action in the gastrointestinal tract, its properties are very different from other antidiabetic medications. Patients on long-term treatment to control a chro...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476372/ |
| id |
pubmed-3476372 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-34763722012-10-23 Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations Rosak, Christoph Mertes, Gabriele Review The alpha-glucosidase inhibitor acarbose has been used for more than 20 years in the management of hyperglycemia. Owing to its unique mode of action in the gastrointestinal tract, its properties are very different from other antidiabetic medications. Patients on long-term treatment to control a chronic disease are not only interested in good treatment efficacy, but are also even more interested in the safety and side effects of their medications. Significant aspects of acarbose predominantly regarding safety and tolerability in the management of type 2 diabetes and prediabetes are reviewed. It is concluded that acarbose is a convenient long-term treatment option, with benefits for both type 2 diabetics and patients in a prediabetic state. Dove Medical Press 2012-10-12 /pmc/articles/PMC3476372/ /pubmed/23093911 http://dx.doi.org/10.2147/DMSO.S28340 Text en © 2012 Rosak and Mertes, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Rosak, Christoph Mertes, Gabriele |
| spellingShingle |
Rosak, Christoph Mertes, Gabriele Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations |
| author_facet |
Rosak, Christoph Mertes, Gabriele |
| author_sort |
Rosak, Christoph |
| title |
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations |
| title_short |
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations |
| title_full |
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations |
| title_fullStr |
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations |
| title_full_unstemmed |
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations |
| title_sort |
critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations |
| description |
The alpha-glucosidase inhibitor acarbose has been used for more than 20 years in the management of hyperglycemia. Owing to its unique mode of action in the gastrointestinal tract, its properties are very different from other antidiabetic medications. Patients on long-term treatment to control a chronic disease are not only interested in good treatment efficacy, but are also even more interested in the safety and side effects of their medications. Significant aspects of acarbose predominantly regarding safety and tolerability in the management of type 2 diabetes and prediabetes are reviewed. It is concluded that acarbose is a convenient long-term treatment option, with benefits for both type 2 diabetics and patients in a prediabetic state. |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476372/ |
| _version_ |
1611917605275172864 |